As previously reported, Benchmark upgraded AbCellera to Buy from Hold with a $9 price target. AbCellera reported results for Q4 and highlights during the fourth quarter included three new partnered program starts, two proprietary R&D programs entering into IND-enabling studies, and three additional partnered molecules entering clinical trials, the analyst tells investors. The firm’s post-earnings upgrade is due to improved metrics for other stocks as well as R&D progress for the company, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABCL: